Oxford BioDynamics Secures Shareholder Approval for 9.15 Billion New Shares Admission to AIM After August Placing

Oxford BioDynamics Secures Shareholder Approval for 9.15 Billion New Shares Admission to AIM After August Placing →

Oxford BioDynamics Plc (AIM: OBD), the global biotechnology firm specialising in precision clinical diagnostics and its EpiSwitch® Orion cloud-based 3D genomics platform, has confirmed shareholder approval of all resolutions at its General…